{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:36:29Z","timestamp":1759206989102},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1186\/s12859-019-2695-7","type":"journal-article","created":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T09:07:39Z","timestamp":1555578459000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["VIGLA-M: visual gene expression data analytics"],"prefix":"10.1186","volume":"20","author":[{"given":"Ismael","family":"Navas-Delgado","sequence":"first","affiliation":[]},{"given":"Jos\u00e9","family":"Garc\u00eda-Nieto","sequence":"additional","affiliation":[]},{"given":"Esteban","family":"L\u00f3pez-Camacho","sequence":"additional","affiliation":[]},{"given":"Maciej","family":"Rybinski","sequence":"additional","affiliation":[]},{"given":"Rocio","family":"Lavado","sequence":"additional","affiliation":[]},{"given":"Miguel \u00c1ngel","family":"Berciano Guerrero","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 F.","family":"Aldana-Montes","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,4,18]]},"reference":[{"issue":"20","key":"2695_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/nar\/gkw799","volume":"44","author":"H Wang","year":"2016","unstructured":"Wang H, Horbinski C, Wu H, Liu Y, Sheng S, Liu J, Weiss H, Stromberg AJ, Wang C. Nanostringdiff: a novel statistical method for differential expression analysis based on nanostring ncounter data. Nucleic Acids Res. 2016; 44(20):151.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"2695_CR2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/bioinformatics\/bts188","volume":"28","author":"D Waggott","year":"2012","unstructured":"Waggott D, Chu K, Yin S, Wouters BG, Liu F-F, Boutros PC. Nanostringnorm: an extensible r package for the pre-processing of nanostring mrna and mirna data. Bioinformatics. 2012; 28(11):1546\u20138.","journal-title":"Bioinformatics"},{"issue":"1","key":"2695_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40425-015-0088-7","volume":"3","author":"A Cesano","year":"2015","unstructured":"Cesano A. ncounter pancancer immune profiling panel (nanostring technologies, inc., seattle, wa). J Immunother Cancer. 2015; 3(1):42.","journal-title":"J Immunother Cancer"},{"key":"2695_CR4","unstructured":"Nsolver. \n                    https:\/\/www.nanostring.com\/products\/analysis-software\/nsolver\n                    \n                  . Accessed 20 Feb 2018."},{"issue":"1","key":"2695_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/1471-2105-12-479","volume":"12","author":"CD Brumbaugh","year":"2011","unstructured":"Brumbaugh CD, Kim HJ, Giovacchini M, Pourmand N. Nanostride: normalization and differential expression analysis of nanostring ncounter data. BMC Bioinformatics. 2011; 12(1):479.","journal-title":"BMC Bioinformatics"},{"key":"2695_CR6","doi-asserted-by":"crossref","unstructured":"Araujo R, Trielli G, Orair G, Meira W Jr, Ferreira R, Guedes D. ParTriCluster: A Scalable Parallel Algorithm for Gene Expression Analysis. In: SBAC-PAD\u201906: Proceedings of the 18th International Symposium on Computer Architecture and High Performance Computing. IEEE: 2006. p. 3\u201310.","DOI":"10.1109\/SBAC-PAD.2006.20"},{"issue":"17","key":"2695_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/nar\/gkx679","volume":"45","author":"S Peng","year":"2017","unstructured":"Peng S, Yang S, Bo X, Li F. paragsea: a scalable approach for large-scale gene expression profiling. Nucleic Acids Res. 2017; 45(17):155.","journal-title":"Nucleic Acids Res"},{"issue":"13","key":"2695_CR8","first-page":"1290","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day S, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel CJ, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb\u00e9 C., Peschel C, Quirt I, Clark JI, Wolchok JD, Weber J, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Bimproved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(13):1290.","journal-title":"N Engl J Med"},{"issue":"26","key":"2695_CR9","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O\u2019Day S, Weber J, Garbe C, Lebbe C, Baurain J-F, Testori A, Grob J-J, Davidson N, Richards J, Maio M, Hauschild A, Miller WHJ, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen T-T, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26):2517\u201326.","journal-title":"N Engl J Med"},{"issue":"26","key":"2695_CR10","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti\u2013pd-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"26","key":"2695_CR11","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti\u2013pd-l1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"2","key":"2695_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber J, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti\u2013pd-1) in melanoma. N Engl J Med. 2013; 369(2):134\u201344.","journal-title":"N Engl J Med"},{"issue":"16","key":"2695_CR13","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-11-2837","volume":"72","author":"RC Koya","year":"2012","unstructured":"Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A. Braf inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012; 72(16):3928\u201337.","journal-title":"Cancer Res"},{"issue":"5","key":"2695_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4161\/onci.20226","volume":"1","author":"A Hooijkaas","year":"2012","unstructured":"Hooijkaas A, Gadiot J, Morrow M, Stewart R, Schumacher T, Blank CU. Selective braf inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. OncoImmunology. 2012; 1(5):609\u201317.","journal-title":"OncoImmunology"},{"issue":"3","key":"2695_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1172\/JCI66236","volume":"123","author":"DA Knight","year":"2013","unstructured":"Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ. Host immunity contributes to the anti-melanoma activity of braf inhibitors. J Clin Investig. 2013; 123(3):1371\u201381.","journal-title":"J Clin Investig"},{"issue":"7","key":"2695_CR16","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","volume":"2","author":"ZA Cooper","year":"2014","unstructured":"Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to braf inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014; 2(7):643\u201354.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2695_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4161\/cbt.28555","volume":"15","author":"M Sanlorenzo","year":"2014","unstructured":"Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. Melanoma immunotherapy. Cancer Biol Ther. 2014; 15(6):665\u201374.","journal-title":"Cancer Biol Ther"},{"key":"2695_CR18","unstructured":"Nanostring Guidelines. \n                    https:\/\/www.nanostring.com\/download_file\/view\/251\/3779\n                    \n                  . Accessed 20 Feb 2018."},{"issue":"7","key":"2695_CR19","doi-asserted-by":"publisher","first-page":"0034","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative rt-pcr data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):0034\u20131.","journal-title":"Genome Biol"},{"key":"2695_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0012776","volume":"5","author":"VA Huynh-Thu","year":"2010","unstructured":"Huynh-Thu VA, Irrthum A, Wehenkel L, Geurts P. Inferring regulatory networks from expression data using tree-based methods. PLoS ONE. 2010; 5:1\u201310.","journal-title":"PLoS ONE"},{"issue":"2","key":"2695_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2051-1426-3-S2-O7","volume":"3","author":"TC Gangadhar","year":"2015","unstructured":"Gangadhar TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Luke JJ, Balmanoukian AS, Kaufman DR, Zhao Y, Maleski J, Leopold L, Gajewski TF. Preliminary results from a phase i\/ii study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. J Immunother Cancer. 2015; 3(2):7.","journal-title":"J Immunother Cancer"},{"key":"2695_CR22","unstructured":"Berciano M, et al.Expresi\u00f3n g\u00e9nica de sistema inmune en pacientes con melanoma metast\u00e1sico tratados con ibraf. In: IV Congreso de la Sociedad Andaluza de Oncolog\u00eda M\u00e9dica. Sociedad Andaluza de Oncolog\u00eda M\u00e9dica: 2017."},{"key":"2695_CR23","unstructured":"Berciano M, et al.Expresi\u00f3n de genes inmunol\u00f3gicos para predecir la respuesta en pacientes con melanoma tratados con inhibidores de braf. In: III FORO de Inmunolog\u00eda Traslacional e Inmunoterapia del C\u00e1ncer. G\u00e9tica: 2017."}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-019-2695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12859-019-2695-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-019-2695-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T23:11:33Z","timestamp":1587078693000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-019-2695-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":23,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["2695"],"URL":"https:\/\/doi.org\/10.1186\/s12859-019-2695-7","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"18 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval and consent obtained from patients in the context of the project \u201cREINDUCCI\u00d3N INMUNOL\u00d3GICA EN PACIENTES CON MELANOMA METAST\u00c1SICO TRAS TRATAMIENTO CON TERAPIA DIRIGIDA. EXPLORACI\u00d3N DE FACTORES PREDICTIVOS Y PRON\u00d3STICOS\u201d. Project approved by the hospital ethics committee (Comit\u00e9 de \u00c9tica del Hospital Regional Universitario y Virgen de la Victoria de M\u00e1laga).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"150"}}